In the contact phase of activation of the kinin-forming, intrinsic clotting, and fibrinolytic systems, high-molecular-weight kininogen acts as a cofactor for the activation of Factor XI, prekallikrein, and Hageman factor. One mechanism by which high-molecular-weight kininogen acts as a cofactor has been studied by using 125f-labeled Factor XI and prekallikrein in kaolin-activated normal human plasma and plasmas deficient in high-molecular-weight kininogen and Hageman factor. High-molecular-weight kininogen was found to be essential for normal binding and cleavage of both Factor XI and prekallikrein on the kaolin surface. Hageman factor was essential for cleavage but not for binding of Factor XI and prekallikrein to kaolin. In normal plasma 80% of the activated Factor XI remained surface-bound, whereas 80% of the kallikrein was not surface-bound. These findings are consistent with the hypothesis that, in the initial phase of contact activation, high-molecular-weight kininogen links both Factor XI and prekallikrein to the exposed surface where they are activated by surface-bound activated Hageman factor. Once activated, the Factor XI molecules remain localized at the site of activation, in contrast to the kallikrein molecules which are found largely in the surrounding plasma.
Activation of Hageman factor (Factor XII) upon a negatively charged surface initiates intrinsic coagulation, fibrinolysis, and the generation of vasoactive peptides (1) (2) (3) (4) (5) . High-molecularweight (Mr) kininogen is a cofactor for the optimal activation of surface-bound Hageman factor by kallikrein (6) (7) (8) and for the activation of prekallikrein and Factor XI by surface-bound activated Hageman factor (6) (7) (8) . Prekallikrein is complexed to high Mr kininogen in plasma (9) . Recent studies (10; R. C. Wiggins, B. N. Bouma, C. G. Cochrane, and J. H. Griffin, unpublished data) suggest that Factor XI is also complexed to high Mr kininogen in plasma. In this study we demonstrate that one mechanism by which high Mr kininogen acts as a cofactor for the activation of both Factor XI and prekallikrein in plasma is to bind both these molecules to the surface where they are activated by surface-bound activated Hageman factor. We also demonstrate that, while activated Factor XI remains associated with the surface, kallikrein dissociates from the surface.
MATERIALS AND METHODS

Purified proteins
Factor XI was isolated from normal human plasma as described elsewhere (11) and was determined to be more than 95% homogeneous on sodium dodecyl sulfate (NaDodSO4/polyacrylamide gels. The purified protein had a specific clotting activity of 220 units/mg, where 1 clotting unit is defined as the amount of activity present in 1 ml of citrated normal human plasma. Factor XI was radiolabeled with '25iodine by the insolubilized lactoperoxidase method (12) . The 125I-labeled Factor XI (125I-Factor XI), 5 ,uCi/,ug, retained its procoagulant activities at 3.6 clotting units/ml.
Prekallikrein was isolated from normal human plasma by a method similar to that described for Factor XI (11) . This involved the chromatography of prekallikrein on DEAE-, QAE-, and SP-Sephadex, and on concanavalin A-Sepharose, and sucrose density gradient ultracentrifugation (B. N. Bouma and J. H. Griffin, unpublished data). The protein was more than 95% homogeneous on NaDodSO4/polyacrylamide gels. The purified protein had a specific clotting activity of 19 units/mg, where 1 clotting unit is defined as the amount of activity present in 1 ml of citrated normal human plasma. Prekallikrein was radiolabeled with '25iodine by the chloramine-T method (13); after radiolabeling 12% of the material appeared as kallikrein. Only the heavy chain (45,000 Mr) was radiolabeled by the above procedure; therefore the light chain (35,000 Mr) containing the active site (and which could bind to inhibitors in plasma) was not seen on reduced NaDodSO4/polyacrylamide gels. The 125I-labeled prekallikrein' (125I-prekallikrein), 3 ,uCi/,ug, retained its procoagulant activity at 2.3 clotting units/ml.
High Mr Kininogen was isolated from freshly prepared normal human plasma containing acid/citrate/dextrose anticoagulant (1 liter contains 13.6 g of citric acid, 25 g of sodium citrate, and 20 g of dextrose). Plasma (1.4 liters) was chromatographed on DEAE-Sephadex exactly as described for the isolation of Hageman factor (14) . The pool of fractions containing activity that corrected the clotting defect of plasma deficient in high Mr kininogen was brought to 47% saturation of (NH4)2SO4 by addition of saturated (NH4)2SO4 at 4°. After the mixture was stirred for 1 hr, the precipitate was collected by centrifugation at 5600 X g for 90 min. The precipitate was dissolved in 100 ml of buffer containing 50 mM acetate, 75 mM NaCl, 0.5 mM EDTA, 0.5 mM benzamidine, 25 ,ug of Polybrene per ml, 0.01% sodium azide, at pH 5.3, and the sample was applied to an SP-Sephadex column which was developed exactly as described as step 5 in the isolation of Hageman factor (14) . The high Mr kininogen, which was eluted in the terminal region of the peak of activity from this column, was greater than 90% homogeneous as judged on NaDodSO4 gels, and it exhibited a specific clotting activity of 12 (20,ul) containing mercaptoethanol (5%), EDTA (100 mM), and urea (8 M) was added to the kaolin and to a 10-i aliquot of the supernatant. These samples were boiled for 7 min and then analyzed on 7.5% NaDodSO4/polyacrylamide gels by the method described by Weber et al. (15) . After electrophoresis the gels were cut into 1.2-mm slices, and the radioactivity was determined.
Calculation of binding and cleavage data
The total bound and free 125I-Factor XI and 125I-prekallikrein was calculated by integrating the radioactivity in the 83,000, 50,000, and 33,000 Mr peaks for Factor XI and the 85,000 and 48,000 Mr peaks for prekallikrein from the kaolin and from the supernatant. A volume correction was made for the aliquot from the supernatant. The proportions of cleaved proteins were estimated by calculating the percentage of the total radioactivity present in the 50,000 plus 33,000 Mr peaks for Factor XI and the 48,000 Mr peak for prekallikrein. Correspondingly, the percentage of each protein that was not cleaved was calculated as the percentage of total radioactivity in the 83,000 or 85,000 Mr peak for Factor XI or prekallikrein, respectively. Finally, in control gels when no kaolin had been added (which gave profiles identical to those in Figs. 1B and 2B) the proportion of radioactivity corresponding to the position of the cleavage fragments was calculated and found to be 5% for 125I-Factor XI and 12% for 125I-prekallikrein. These corrections were subtracted from the calculated cleavage values to give the figures presented in Tables 1 and 2 . More than 60% of the 125iodine added to the plasma was recovered on the polyacrylamide gels.
RESULTS
Factor XI
The binding and cleavage of 125I-Factor XI in kaolin-activated normal plasma and in plasmas deficient in Hageman factor and high Mr kininogen are shown in Fig. 1 and Table 1 . Whereas in normal plasma after a 2-min incubation at 370, 87% of the Factor XI was bound to kaolin (Fig. 1A) , in the absence of high Mr kininogen only 14% was bound (Fig. 1C) . When The binding and cleavage of 1251-Factor XI in various plasmas after addition of kaolin and incubation for 2 min at 37°. The kaolin-bound material and supernatant were separated, reduced, and analyzed on 7.5% NaDodSO4/polyacrylamide gels. The values given are derived from integration of radiolabeled Factor XI in the 83,000 Mr uncleaved molecule and the 50,000 and 33,000 Mr cleavage fragments shown in Fig. 1 . kaolin increased to 79% (Fig. 1D) . In the absence of Hageman factor, binding was slightly reduced at 66% (Fig. 1B) Fig. 2 and Table 2 . After a 2-min incubation at 200 in normal plasma most of the prekallikrein was cleaved both on the kaolin (64%) and in the supernatant (62%) (Fig. 2A) . In the absence of high Mr kininogen (Fig. 2C ) and Hageman factor (Fig. 2B) cleavage was minimal (i.e., less than 0.5%), whereas upon reconstitution of the high Mr kininogen-deficient plasma with purified high Mr kininogen, cleavage occurred normally (Fig. 2D) Fig. 3 summarizes four hypothesized reactions that involve Factor XI and high Mr kininogen. The first reaction, a reversible equilibrium for which the equilibrium constant is unknown, describes complex formation in plasma between the two molecules. The reaction is supported by studies of these two molecules in plasma analyzed by Sephadex G-200 chromatography (ref. 10 ; R. C. Wiggins, B. N. Bouma, C. G. Cochrane, and J. H. Griffin, unpublished The binding and cleavage of 125I-prekallikrein in various plasmas after addition of kaolin and incubation for 2 min at 200. The kaolin-boundmaterial and supernatant were separated, reduced, and analyzed in 7.5% NaDodSO4/polyacrylamide gels. The values given are derived from integration of reduced radiolabeled prekallikrein in the 85,000 Mr uncleaved molecule and the 48,000 Mr cleavage fragment shown in Fig. 2 Harpel (34) showed that partially purified kallikrein would bind to collagen and that, after brief incubation of particulate collagen with undiluted plasma, kallikrein activity could -be identified on the washed collagen. Assuming 
